Design Therapeutics (DSGN)

• Market cap: $367M
• 1 day: 2.20%
• 5 days: 10.75%
• 1 month: 5.53%
• 3 months: 19.74%
• 6 months: 100.93%
• Year to date: 155.51%
• 1 year: 140.37%
• 5 years: -84.36%
• 10 years: -84.36%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Employees: 54

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

50% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 10

37% more capital invested

Capital invested by funds: $126M [Q2] → $172M (+$46.4M) [Q3]

5% more funds holding

Funds holding: 95 [Q2] → 100 (+5) [Q3]

9.83% less ownership

Funds ownership: 66.41% [Q2] → 56.57% (-9.83%) [Q3]

20% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 35

90% less call options, than puts

Call options by funds: $18K | Put options by funds: $175K